1. Home
  2. UTL vs EVMN Comparison

UTL vs EVMN Comparison

Compare UTL & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo UNITIL Corporation

UTL

UNITIL Corporation

HOLD

Current Price

$50.78

Market Cap

906.9M

Sector

Utilities

ML Signal

HOLD

EVMN

Evommune Inc.

N/A

Current Price

$22.85

Market Cap

825.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
UTL
EVMN
Founded
1984
2020
Country
United States
United States
Employees
N/A
48
Industry
Power Generation
Biotechnology: Pharmaceutical Preparations
Sector
Utilities
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
906.9M
825.5M
IPO Year
1995
N/A

Fundamental Metrics

Financial Performance
Metric
UTL
EVMN
Price
$50.78
$22.85
Analyst Decision
Buy
Strong Buy
Analyst Count
2
10
Target Price
$56.50
$43.88
AVG Volume (30 Days)
82.6K
260.8K
Earning Date
05-04-2026
06-11-2026
Dividend Yield
3.65%
N/A
EPS Growth
1.37
N/A
EPS
1.85
N/A
Revenue
$536,000,000.00
N/A
Revenue This Year
$5.43
N/A
Revenue Next Year
$4.22
N/A
P/E Ratio
$27.40
N/A
Revenue Growth
8.33
N/A
52 Week Low
$45.11
$13.89
52 Week High
$55.34
$33.20

Technical Indicators

Market Signals
Indicator
UTL
EVMN
Relative Strength Index (RSI) 42.84 41.03
Support Level $49.14 $21.14
Resistance Level $53.33 $25.50
Average True Range (ATR) 1.43 1.78
MACD -0.27 -0.41
Stochastic Oscillator 37.91 10.37

Price Performance

Historical Comparison
UTL
EVMN

About UTL UNITIL Corporation

Unitil Corp through its subsidiaries engages in the distribution of electricity and natural gas in its service territories in the states of New Hampshire, Massachusetts and Maine. Its natural gas operations include gas distribution utility operations and interstate gas transmission pipeline operations. It also engages in interstate natural gas transmission pipeline company, operating approximately 85 miles of underground gas transmission pipeline located in Maine and New Hampshire. The company's segments include Electric and Gas.

About EVMN Evommune Inc.

Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.

Share on Social Networks: